Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Anaesthesiol Intensive Ther ; 53(5): 398-402, 2021.
Article in English | MEDLINE | ID: covidwho-2325899

ABSTRACT

INTRODUCTION: We aimed to investigate the clinical features and mortality of critically ill patients treated with convalescent plasma for COVID-19 in the intensive care unit (ICU). MATERIAL AND METHODS: We retrospectively collected clinical and laboratory data of COVID-19 patients treated in the ICU. The patients were divided into two groups: those who received convalescent plasma and those who did not. We evaluated changes in the laboratory parameters and PaO2/FiO2 of the patients in the convalescent plasma group on days 0, 7, and 14. RESULTS: A total of 188 patients were included, 89 of whom received convalescent plasma. There were no significant differences in length of hospitalization [median: 17 vs. 16 days, P = 0.13] or 28-day mortality between the two groups (59% vs. 65%, P = 0.38). The ICU stay of patients who received convalescent plasma was longer (P = 0.001). The dynamics of the laboratory parameters of 44 patients in the convalescent plasma group, who were still in intensive care on the 14th day, were analysed. There was no differences in CRP or PaO2/FiO2 on day 0, 7 or 14 (P = 0.12; P = 0.10, respectively). CONCLUSIONS: Convalescent plasma treatment was not associated with shorter hospitalisation or lower mortality in patients diagnosed with COVID-19. However, the ICU stay was longer in patients who received convalescent plasma.


Subject(s)
COVID-19 , COVID-19/therapy , Humans , Immunization, Passive , Intensive Care Units , Length of Stay , Retrospective Studies , SARS-CoV-2 , COVID-19 Serotherapy
3.
Journal of the Society of Thoracic Carido-Vascular Anaesthesia & Intensive Care ; 28(2):178-183, 2022.
Article in Turkish | Academic Search Complete | ID: covidwho-1912266

ABSTRACT

Objectives: This study aimed to examine the frequency, and clinical features of pneumothorax and pneumomediastinum cases in patients admitted to the intensive care unit due to coronavirus disease-19 (COVID- 19) pneumonia. Methods: We retrospectively screened the COVID-19 cases hospitalized in our intensive care unit between March 11, 2020, and January 11, 2022. Patients diagnosed as pneumothorax or pneumomediastinum were determined. The frequency and clinical features of pneumothorax and pneumomediastinum were investigated. Results: Seven hundred and twenty patients hospitalized in our intensive care unit between March 11, 2020, and January 11, 2022 were screened. Twenty-four (3.3%) patients had pneumothorax or pneumomediastinum. Pneumothorax occurred 17 patients (70%), and pneumomediastinum in 14 patients (58%). The number of patients who developed pneumomediastinum and pneumothorax together was 7 (29%). COVID-19-associated pneumothorax tended to be unilateral (n=16) and right-sided (n=11). In 18 (75%) patients, pneumothorax or pneumomediastinum developed during invasive mechanical ventilation, 5 (20.8%) patients during non-invasive mechanical ventilation. One patient developed pneumothorax when mechanical ventilation was not applied. The mortality rate at 60 days was 75% (n=18) in patients who were admitted to the intensive care unit with COVID- 19 and developed pneumomediastinum or pneumothorax. Conclusion: Pneumothorax and pneumomediastinum are complications of COVID-19 pneumonia with high mortality rates. (English) [ FROM AUTHOR] Amaç: Bu çalışmada, koronavirüs hastalığı-19 (COVID-19) pnömonisi nedeniyle üçüncü basamak yoğun bakım ünitesine başvuran hastalarda gelişen pnömotoraks ve pnömomediastinum sıklığının ve klinik özelliklerinin incelenmesi amaçlandı. Yöntem: Yoğun bakım ünitesinde, 11 Mart 2020 ile 11 Ocak 2022 tarihleri arasında yatan COVID-19 hastaları geriye dönük olarak incelendi, pnömotoraks ve pnömomediastinum tanıları alan hastalar belirlendi. Pnömotoraks ve pnömomediastinum sıklığı ile klinik özellikleri araştırıldı. Bulgular: Yoğun bakım ünitesinde 11 Mart 2020 ile 11 Ocak 2022 tarihleri arasında yatan 720 hasta tarandı. Yirmi dört hastanın pnömotoraks veya pnömomediastinum olduğu izlendi (%3,3). On yedi (%70) hastada pnömotoraks, 14 (%58) hastada ise pnömomediastinum izlendi. Pnömomediastinum ve pnömotoraksın birlikte geliştiği hasta sayısı 7 (%29) idi. COVID-19 ile ilişkili pnömotoraks tek taraflı (n=16) ve sağ taraflı olma (n=11) eğiliminde idi. Hastaların 18’i (%75) pnömotoraks veya pnömomediastinum gelişimi sırasında invaziv mekanik ventilasyon, 5’ine (%20,8) noninvaziv mekanik ventilasyon uygulanmaktaydı. Bir hastada mekanik ventilasyon uygulanmıyorken pnömotoraks gelişti. COVID-19 hastalığı ile yoğun bakıma yatan, pnömotoraks veya pnömomediastinum gelişen hastalarda 60. günde ölüm oranı %75 (n=18) idi. Sonuç: Pnömotoraks ve pnömomediastinum COVID-19’a bağlı pnömoni hastalarında gelişebilen mortalitesi yüksek komplikasyonlardır. (Turkish) [ FROM AUTHOR] Copyright of Journal of the Society of Thoracic Carido-Vascular Anaesthesia & Intensive Care is the property of Gogus Kalp Damar Anestezi ve Yogun Bakim Dernegi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

4.
Scand J Clin Lab Invest ; 82(2): 108-114, 2022 04.
Article in English | MEDLINE | ID: covidwho-1662010

ABSTRACT

In critical patients with Coronavirus Disease (COVID-19), we investigated the diagnostic value of presepsin in the early diagnosis of superinfection with sepsis, and the effect of antibiotic treatment (AT) in the levels of presepsin and procalcitonin and C-reactive protein. A total of 68 critical patients with sepsis and septic shock in the intensive care unit and 20 outpatients (control group) with COVID-19 were taken. ICU patients (n = 68) were further divided into three groups. C(-)AT(-) had negative blood or tracheal aspirate cultures (C) and not AT on admission to ICU (n = 18), C(-)AT(+) had negative C and AT on admission to intensive care unit (n = 31) and C(+) had positive C (n = 19). Presepsin, procalcitonin, C-reactive protein results were compared between the groups. There were no significant relationships between presepsin levels with sepsis, septic shock, mortality, or length of stay in ICU in patients with COVID-19. For procalcitonin and C-reactive protein levels in C(-)AT(+) and C(+) groups were significantly higher than in control and C(-)AT(-) groups (p < .001). C-reactive protein levels in C(-)AT(-) group were significantly higher than in the control group (p < .001). PCT and CRP, there was no difference between C(-)AT(+) and C(+) groups, and procalcitonin there was no difference between control and C(-)AT(-) groups. Presepsin was not found as a useful biomarker for the prediction of sepsis in COVID-19 patients. These study findings indicate that procalcitonin and C-reactive protein may be an indicator of an early diagnostic marker for superinfection in critical COVID-19 patients.


Subject(s)
COVID-19 , Sepsis , Shock, Septic , Superinfection , Biomarkers , C-Reactive Protein/analysis , COVID-19/diagnosis , Early Diagnosis , Humans , Lipopolysaccharide Receptors , Peptide Fragments , Procalcitonin , Shock, Septic/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL